Pembro Approved for 1st-Line Use in MSI-H/dMMR Colorectal Cancer Pembro Approved for 1st-Line Use in MSI-H/dMMR Colorectal Cancer

The FDA gave a thumbs-up to pembrolizumab as first-line monotherapy for microsatellite instability-high or mismatch repair deficient colorectal cancer.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news